About UDP-glucose 4-epimerase
UDP-glucose 4-epimerase (GALE) is a protein
from Homo sapiens identified by UniProt accession
Q14376, 348 residues long.
MolForge cross-references it against 0 known binders and
90 disease associations.
Target properties
| Protein name | UDP-glucose 4-epimerase |
| UniProt accession | Q14376 |
| Gene | GALE |
| Organism | Homo sapiens |
| Length | 348 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (3)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (90)
Diseases linked to this target (Open Targets).
- galactose epimerase deficiency · score 0.84
- Intellectual disability · score 0.46
- genetic disorder · score 0.41
- galactosemia · score 0.37
- erythrocyte galactose epimerase deficiency · score 0.37
- generalized galactose epimerase deficiency · score 0.37
- neuroinflammatory disorder · score 0.24
- reticulocyte count · score 0.12
- reticulocyte measurement · score 0.07
- psychotic symptoms · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14376-F1 | alphafold | PREDICTED | 97.08 | — |
Amino-acid sequence (348 residues)
MAEKVLVTGG AGYIGSHTVL ELLEAGYLPV VIDNFHNAFR GGGSLPESLR RVQELTGRSV EFEEMDILDQ GALQRLFKKY SFMAVIHFAG LKAVGESVQK PLDYYRVNLT GTIQLLEIMK AHGVKNLVFS SSATVYGNPQ YLPLDEAHPT GGCTNPYGKS KFFIEEMIRD LCQADKTWNA VLLRYFNPTG AHASGCIGED PQGIPNNLMP YVSQVAIGRR EALNVFGNDY DTEDGTGVRD YIHVVDLAKG HIAALRKLKE QCGCRIYNLG TGTGYSVLQM VQAMEKASGK KIPYKVVARR EGDVAACYAN PSLAQEELGW TAALGLDRMC EDLWRWQKQN PSGFGTQA
Explore UDP-glucose 4-epimerase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets